Recurrence
- The role of probiotics for the prevention or treatment of CDI remains controversial. Clinical data is limited. Potential for bacteremia/fungemia in immunocompromised patients. Multiple formulations exist but labeling regulations and quality control are lacking. Further research is needed to clarify the role of probiotics in CDI.
Initial recurrence
| Empiric Therapy | Duration | |
|---|---|---|
| Repeat regimen used for initial episode |
10 days | |
| or | ||
| Vancomycin | 40mg/kg/d PO div qid (max 125mg PO qid) | 10 days |
Subsequent recurrence
| Empiric Therapy | Duration | |
|---|---|---|
|
Vancomycin taper-pulse (max 125mg/dose) |
10mg/kg/dose PO qid then |
10-14 days |
10 mg/kg/dose po bid then |
7 days | |
10 mg/kg/dose po daily then |
7 days | |
| 10 mg/kg/dose po q2 or 3 days | 2-8 weeks |